Summary

The global Neoantigens Market is witnessing rapid expansion as cancer care shifts toward highly targeted and patient-specific immunotherapy. The market is valued at US$ 8.9 Bn in 2026 and is projected to reach US$ 71.3 Bn by 2033, growing at a CAGR of 34.70% during the forecast period. Neoantigens are tumor-specific antigens formed by genetic mutations within cancer cells, making them highly attractive targets for precision oncology. Their ability to help the immune system distinguish malignant cells from healthy tissue is driving strong interest across cancer vaccines, T-cell therapies, adoptive cell transfer, and advanced discovery platforms.

Market Insights

The Neoantigens Market is gaining momentum due to advances in next-generation sequencing, bioinformatics, artificial intelligence, and personalized medicine. These technologies allow researchers and companies to identify tumor mutations, predict immunogenic targets, and design customized therapies for individual patients. Personalized neoantigen vaccines are becoming a key area of development, particularly for cancers where conventional treatment outcomes remain limited.

The market is also benefiting from the growing use of immunotherapy in oncology. Cancer vaccines, immune checkpoint inhibitors, and T-cell therapies are increasingly being evaluated in combination to improve immune response and treatment durability. Neoantigen-based approaches are especially important because they offer a more selective treatment pathway by targeting mutations that are unique to tumor cells.

Biotechnology and pharmaceutical companies are investing in platforms that can shorten discovery timelines and improve antigen selection accuracy. At the same time, hospitals, cancer research institutes, and academic centers are supporting clinical studies that explore neoantigens across lung cancer, melanoma, colorectal cancer, breast cancer, pancreatic cancer, prostate cancer, ovarian cancer, and other tumor types.

Drivers

One of the major drivers of the Neoantigens Market is the rising global demand for precision cancer therapies. Many patients do not respond adequately to standard treatments, creating a need for therapies that are more personalized, effective, and capable of generating strong immune memory. Neoantigen-based therapies are designed to activate immune cells against tumor-specific mutations, which may reduce damage to normal cells and improve treatment selectivity.

The increasing availability of genomic sequencing is another important factor supporting market growth. As sequencing becomes faster and more cost-efficient, tumor profiling is becoming more common in oncology research and clinical practice. This enables the identification of patient-specific mutations and supports the development of personalized vaccines and cell therapies.

Progress in mRNA technology has further strengthened the market outlook. Flexible mRNA platforms can support rapid vaccine design and manufacturing, making them suitable for individualized cancer treatment. In addition, artificial intelligence and machine learning are improving neoantigen prediction, helping companies prioritize candidates with stronger therapeutic potential.

Business Opportunity

The Neoantigens Market presents significant opportunities for companies involved in immunotherapy, diagnostics, computational biology, and biomanufacturing. Personalized neoantigen vaccines remain a major opportunity because they align closely with the future of individualized cancer care. Companies that can integrate sequencing, antigen prediction, vaccine design, manufacturing, and clinical delivery are expected to gain competitive advantages.

Neoantigen discovery platforms also represent a high-growth business area. These platforms help pharmaceutical and biotechnology companies identify relevant tumor targets and develop differentiated oncology pipelines. As the demand for data-driven drug development increases, platform providers with strong computational and clinical validation capabilities are likely to attract partnerships.

Off-the-shelf neoantigen vaccines offer another commercial pathway by addressing scalability and accessibility challenges. Shared neoantigens may allow companies to develop therapies for broader patient groups, reducing production complexity compared with fully personalized treatments. Combination strategies with immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer are expected to create additional business opportunities across the oncology ecosystem.

Region Analysis

North America is expected to hold a leading position in the Neoantigens Market due to strong clinical research infrastructure, high adoption of genomic testing, advanced oncology care, and the presence of major biotechnology and pharmaceutical companies. The region benefits from active investment in immuno-oncology, supportive research networks, and a large number of clinical trials focused on personalized cancer therapies.

Europe is also an important market, supported by established cancer research institutions, precision medicine initiatives, and growing collaboration between academic centers and biotechnology firms. Countries with advanced healthcare systems are increasingly focusing on molecular diagnostics and personalized immunotherapy development.

Asia Pacific is projected to record strong growth as cancer incidence rises and healthcare systems expand access to genomic technologies. China, Japan, South Korea, and India are becoming important markets for oncology research, clinical trials, and biotechnology innovation. Latin America and the Middle East & Africa are expected to show gradual adoption as oncology infrastructure, diagnostic capabilities, and awareness of advanced immunotherapies improve.

Key Players

Leading companies operating in the Neoantigens Market include:

• BioNTech SE

• Moderna, Inc.

• Gritstone bio, Inc.

• Neon Therapeutics / BioNTech

• Genentech, Inc. / F. Hoffmann-La Roche Ltd.

• Merck & Co., Inc.

• Advaxis, Inc.

• Nouscom AG

• ISA Pharmaceuticals B.V.

• Achilles Therapeutics plc

• Personalis, Inc.

• Agenus Inc.

• Evaxion Biotech A/S

• Vaccibody / Nykode Therapeutics ASA

• Immatics N.V.

These companies are focusing on personalized vaccine development, neoantigen discovery, cell therapy platforms, clinical collaborations, and combination immunotherapy strategies to strengthen their presence in the market.

Segmentation

By Product Type

• Personalized Neoantigen Vaccines

• Off-the-shelf Neoantigen Vaccines

• Neoantigen-based Cell Therapies

• Neoantigen Discovery Platforms

• Others

By Type

• Personalized Neoantigens

• Shared Neoantigens

By Immunotherapy Type

• Cancer Vaccines

• T-cell Therapies

• Adoptive Cell Transfer

• Immune Checkpoint Inhibitors

• Others

By Application

• Lung Cancer

• Melanoma

• Colorectal Cancer

• Breast Cancer

• Pancreatic Cancer

• Prostate Cancer

• Ovarian Cancer

• Others

By End User

• Hospitals

• Cancer Research Institutes

• Biotechnology & Pharmaceutical Companies

• Academic & Research Centers

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Neoantigens Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Neoantigens Market Outlook, 2020 - 2033
3.1. Global Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
3.1.1. Personalized Neoantigens
3.1.2. Shared Neoantigens
3.2. Global Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
3.2.1. Hospitals
3.2.2. Cancer Research Institutes
3.2.3. Biotechnology & Pharmaceutical Companies
3.2.4. Academic & Research Centers
3.2.5. Others
3.3. Global Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
3.3.1. Lung Cancer
3.3.2. Melanoma
3.3.3. Colorectal Cancer
3.3.4. Breast Cancer
3.3.5. Pancreatic Cancer
3.3.6. Prostate Cancer
3.3.7. Ovarian Cancer
3.3.8. Others
3.4. Global Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
3.4.1. Cancer Vaccines
3.4.2. T-cell Therapies
3.4.3. Adoptive Cell Transfer
3.4.4. Immune Checkpoint Inhibitors
3.4.5. Others
3.5. Global Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
3.5.1. Personalized Neoantigen Vaccines
3.5.2. Off-the-shelf Neoantigen Vaccines
3.5.3. Neoantigen-based Cell Therapies
3.5.4. Neoantigen Discovery Platforms
3.5.5. Others
3.6. Global Neoantigens Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Latin America
3.6.5. Middle East & Africa
4. North America Neoantigens Market Outlook, 2020 - 2033
4.1. North America Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
4.1.1. Personalized Neoantigens
4.1.2. Shared Neoantigens
4.2. North America Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
4.2.1. Hospitals
4.2.2. Cancer Research Institutes
4.2.3. Biotechnology & Pharmaceutical Companies
4.2.4. Academic & Research Centers
4.2.5. Others
4.3. North America Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
4.3.1. Lung Cancer
4.3.2. Melanoma
4.3.3. Colorectal Cancer
4.3.4. Breast Cancer
4.3.5. Pancreatic Cancer
4.3.6. Prostate Cancer
4.3.7. Ovarian Cancer
4.3.8. Others
4.4. North America Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
4.4.1. Cancer Vaccines
4.4.2. T-cell Therapies
4.4.3. Adoptive Cell Transfer
4.4.4. Immune Checkpoint Inhibitors
4.4.5. Others
4.5. North America Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
4.5.1. Personalized Neoantigen Vaccines
4.5.2. Off-the-shelf Neoantigen Vaccines
4.5.3. Neoantigen-based Cell Therapies
4.5.4. Neoantigen Discovery Platforms
4.5.5. Others
4.6. North America Neoantigens Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.6.1. U.S. Neoantigens Market Outlook, by Type, 2020-2033
4.6.2. U.S. Neoantigens Market Outlook, by End User, 2020-2033
4.6.3. U.S. Neoantigens Market Outlook, by Application, 2020-2033
4.6.4. U.S. Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
4.6.5. U.S. Neoantigens Market Outlook, by Product Type, 2020-2033
4.6.6. Canada Neoantigens Market Outlook, by Type, 2020-2033
4.6.7. Canada Neoantigens Market Outlook, by End User, 2020-2033
4.6.8. Canada Neoantigens Market Outlook, by Application, 2020-2033
4.6.9. Canada Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
4.6.10. Canada Neoantigens Market Outlook, by Product Type, 2020-2033
4.7. BPS Analysis/Market Attractiveness Analysis
5. Europe Neoantigens Market Outlook, 2020 - 2033
5.1. Europe Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
5.1.1. Personalized Neoantigens
5.1.2. Shared Neoantigens
5.2. Europe Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
5.2.1. Hospitals
5.2.2. Cancer Research Institutes
5.2.3. Biotechnology & Pharmaceutical Companies
5.2.4. Academic & Research Centers
5.2.5. Others
5.3. Europe Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
5.3.1. Lung Cancer
5.3.2. Melanoma
5.3.3. Colorectal Cancer
5.3.4. Breast Cancer
5.3.5. Pancreatic Cancer
5.3.6. Prostate Cancer
5.3.7. Ovarian Cancer
5.3.8. Others
5.4. Europe Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
5.4.1. Cancer Vaccines
5.4.2. T-cell Therapies
5.4.3. Adoptive Cell Transfer
5.4.4. Immune Checkpoint Inhibitors
5.4.5. Others
5.5. Europe Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
5.5.1. Personalized Neoantigen Vaccines
5.5.2. Off-the-shelf Neoantigen Vaccines
5.5.3. Neoantigen-based Cell Therapies
5.5.4. Neoantigen Discovery Platforms
5.5.5. Others
5.6. Europe Neoantigens Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.6.1. Germany Neoantigens Market Outlook, by Type, 2020-2033
5.6.2. Germany Neoantigens Market Outlook, by End User, 2020-2033
5.6.3. Germany Neoantigens Market Outlook, by Application, 2020-2033
5.6.4. Germany Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.5. Germany Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.6. Italy Neoantigens Market Outlook, by Type, 2020-2033
5.6.7. Italy Neoantigens Market Outlook, by End User, 2020-2033
5.6.8. Italy Neoantigens Market Outlook, by Application, 2020-2033
5.6.9. Italy Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.10. Italy Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.11. France Neoantigens Market Outlook, by Type, 2020-2033
5.6.12. France Neoantigens Market Outlook, by End User, 2020-2033
5.6.13. France Neoantigens Market Outlook, by Application, 2020-2033
5.6.14. France Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.15. France Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.16. U.K. Neoantigens Market Outlook, by Type, 2020-2033
5.6.17. U.K. Neoantigens Market Outlook, by End User, 2020-2033
5.6.18. U.K. Neoantigens Market Outlook, by Application, 2020-2033
5.6.19. U.K. Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.20. U.K. Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.21. Spain Neoantigens Market Outlook, by Type, 2020-2033
5.6.22. Spain Neoantigens Market Outlook, by End User, 2020-2033
5.6.23. Spain Neoantigens Market Outlook, by Application, 2020-2033
5.6.24. Spain Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.25. Spain Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.26. Russia Neoantigens Market Outlook, by Type, 2020-2033
5.6.27. Russia Neoantigens Market Outlook, by End User, 2020-2033
5.6.28. Russia Neoantigens Market Outlook, by Application, 2020-2033
5.6.29. Russia Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.30. Russia Neoantigens Market Outlook, by Product Type, 2020-2033
5.6.31. Rest of Europe Neoantigens Market Outlook, by Type, 2020-2033
5.6.32. Rest of Europe Neoantigens Market Outlook, by End User, 2020-2033
5.6.33. Rest of Europe Neoantigens Market Outlook, by Application, 2020-2033
5.6.34. Rest of Europe Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
5.6.35. Rest of Europe Neoantigens Market Outlook, by Product Type, 2020-2033
5.7. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Neoantigens Market Outlook, 2020 - 2033
6.1. Asia Pacific Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
6.1.1. Personalized Neoantigens
6.1.2. Shared Neoantigens
6.2. Asia Pacific Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
6.2.1. Hospitals
6.2.2. Cancer Research Institutes
6.2.3. Biotechnology & Pharmaceutical Companies
6.2.4. Academic & Research Centers
6.2.5. Others
6.3. Asia Pacific Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
6.3.1. Lung Cancer
6.3.2. Melanoma
6.3.3. Colorectal Cancer
6.3.4. Breast Cancer
6.3.5. Pancreatic Cancer
6.3.6. Prostate Cancer
6.3.7. Ovarian Cancer
6.3.8. Others
6.4. Asia Pacific Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
6.4.1. Cancer Vaccines
6.4.2. T-cell Therapies
6.4.3. Adoptive Cell Transfer
6.4.4. Immune Checkpoint Inhibitors
6.4.5. Others
6.5. Asia Pacific Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
6.5.1. Personalized Neoantigen Vaccines
6.5.2. Off-the-shelf Neoantigen Vaccines
6.5.3. Neoantigen-based Cell Therapies
6.5.4. Neoantigen Discovery Platforms
6.5.5. Others
6.6. Asia Pacific Neoantigens Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.6.1. China Neoantigens Market Outlook, by Type, 2020-2033
6.6.2. China Neoantigens Market Outlook, by End User, 2020-2033
6.6.3. China Neoantigens Market Outlook, by Application, 2020-2033
6.6.4. China Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.5. China Neoantigens Market Outlook, by Product Type, 2020-2033
6.6.6. Japan Neoantigens Market Outlook, by Type, 2020-2033
6.6.7. Japan Neoantigens Market Outlook, by End User, 2020-2033
6.6.8. Japan Neoantigens Market Outlook, by Application, 2020-2033
6.6.9. Japan Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.10. Japan Neoantigens Market Outlook, by Product Type, 2020-2033
6.6.11. South Korea Neoantigens Market Outlook, by Type, 2020-2033
6.6.12. South Korea Neoantigens Market Outlook, by End User, 2020-2033
6.6.13. South Korea Neoantigens Market Outlook, by Application, 2020-2033
6.6.14. South Korea Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.15. South Korea Neoantigens Market Outlook, by Product Type, 2020-2033
6.6.16. India Neoantigens Market Outlook, by Type, 2020-2033
6.6.17. India Neoantigens Market Outlook, by End User, 2020-2033
6.6.18. India Neoantigens Market Outlook, by Application, 2020-2033
6.6.19. India Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.20. India Neoantigens Market Outlook, by Product Type, 2020-2033
6.6.21. Southeast Asia Neoantigens Market Outlook, by Type, 2020-2033
6.6.22. Southeast Asia Neoantigens Market Outlook, by End User, 2020-2033
6.6.23. Southeast Asia Neoantigens Market Outlook, by Application, 2020-2033
6.6.24. Southeast Asia Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.25. Southeast Asia Neoantigens Market Outlook, by Product Type, 2020-2033
6.6.26. Rest of SAO Neoantigens Market Outlook, by Type, 2020-2033
6.6.27. Rest of SAO Neoantigens Market Outlook, by End User, 2020-2033
6.6.28. Rest of SAO Neoantigens Market Outlook, by Application, 2020-2033
6.6.29. Rest of SAO Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
6.6.30. Rest of SAO Neoantigens Market Outlook, by Product Type, 2020-2033
6.7. BPS Analysis/Market Attractiveness Analysis
7. Latin America Neoantigens Market Outlook, 2020 - 2033
7.1. Latin America Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
7.1.1. Personalized Neoantigens
7.1.2. Shared Neoantigens
7.2. Latin America Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
7.2.1. Hospitals
7.2.2. Cancer Research Institutes
7.2.3. Biotechnology & Pharmaceutical Companies
7.2.4. Academic & Research Centers
7.2.5. Others
7.3. Latin America Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
7.3.1. Lung Cancer
7.3.2. Melanoma
7.3.3. Colorectal Cancer
7.3.4. Breast Cancer
7.3.5. Pancreatic Cancer
7.3.6. Prostate Cancer
7.3.7. Ovarian Cancer
7.3.8. Others
7.4. Latin America Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
7.4.1. Cancer Vaccines
7.4.2. T-cell Therapies
7.4.3. Adoptive Cell Transfer
7.4.4. Immune Checkpoint Inhibitors
7.4.5. Others
7.5. Latin America Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
7.5.1. Personalized Neoantigen Vaccines
7.5.2. Off-the-shelf Neoantigen Vaccines
7.5.3. Neoantigen-based Cell Therapies
7.5.4. Neoantigen Discovery Platforms
7.5.5. Others
7.6. Latin America Neoantigens Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.6.1. Brazil Neoantigens Market Outlook, by Type, 2020-2033
7.6.2. Brazil Neoantigens Market Outlook, by End User, 2020-2033
7.6.3. Brazil Neoantigens Market Outlook, by Application, 2020-2033
7.6.4. Brazil Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
7.6.5. Brazil Neoantigens Market Outlook, by Product Type, 2020-2033
7.6.6. Mexico Neoantigens Market Outlook, by Type, 2020-2033
7.6.7. Mexico Neoantigens Market Outlook, by End User, 2020-2033
7.6.8. Mexico Neoantigens Market Outlook, by Application, 2020-2033
7.6.9. Mexico Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
7.6.10. Mexico Neoantigens Market Outlook, by Product Type, 2020-2033
7.6.11. Argentina Neoantigens Market Outlook, by Type, 2020-2033
7.6.12. Argentina Neoantigens Market Outlook, by End User, 2020-2033
7.6.13. Argentina Neoantigens Market Outlook, by Application, 2020-2033
7.6.14. Argentina Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
7.6.15. Argentina Neoantigens Market Outlook, by Product Type, 2020-2033
7.6.16. Rest of LATAM Neoantigens Market Outlook, by Type, 2020-2033
7.6.17. Rest of LATAM Neoantigens Market Outlook, by End User, 2020-2033
7.6.18. Rest of LATAM Neoantigens Market Outlook, by Application, 2020-2033
7.6.19. Rest of LATAM Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
7.6.20. Rest of LATAM Neoantigens Market Outlook, by Product Type, 2020-2033
7.7. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Neoantigens Market Outlook, 2020 - 2033
8.1. Middle East & Africa Neoantigens Market Outlook, by Type, Value (US$ Bn), 2020-2033
8.1.1. Personalized Neoantigens
8.1.2. Shared Neoantigens
8.2. Middle East & Africa Neoantigens Market Outlook, by End User, Value (US$ Bn), 2020-2033
8.2.1. Hospitals
8.2.2. Cancer Research Institutes
8.2.3. Biotechnology & Pharmaceutical Companies
8.2.4. Academic & Research Centers
8.2.5. Others
8.3. Middle East & Africa Neoantigens Market Outlook, by Application, Value (US$ Bn), 2020-2033
8.3.1. Lung Cancer
8.3.2. Melanoma
8.3.3. Colorectal Cancer
8.3.4. Breast Cancer
8.3.5. Pancreatic Cancer
8.3.6. Prostate Cancer
8.3.7. Ovarian Cancer
8.3.8. Others
8.4. Middle East & Africa Neoantigens Market Outlook, by Immunotherapy Type, Value (US$ Bn), 2020-2033
8.4.1. Cancer Vaccines
8.4.2. T-cell Therapies
8.4.3. Adoptive Cell Transfer
8.4.4. Immune Checkpoint Inhibitors
8.4.5. Others
8.5. Middle East & Africa Neoantigens Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
8.5.1. Personalized Neoantigen Vaccines
8.5.2. Off-the-shelf Neoantigen Vaccines
8.5.3. Neoantigen-based Cell Therapies
8.5.4. Neoantigen Discovery Platforms
8.5.5. Others
8.6. Middle East & Africa Neoantigens Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.6.1. GCC Neoantigens Market Outlook, by Type, 2020-2033
8.6.2. GCC Neoantigens Market Outlook, by End User, 2020-2033
8.6.3. GCC Neoantigens Market Outlook, by Application, 2020-2033
8.6.4. GCC Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
8.6.5. GCC Neoantigens Market Outlook, by Product Type, 2020-2033
8.6.6. South Africa Neoantigens Market Outlook, by Type, 2020-2033
8.6.7. South Africa Neoantigens Market Outlook, by End User, 2020-2033
8.6.8. South Africa Neoantigens Market Outlook, by Application, 2020-2033
8.6.9. South Africa Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
8.6.10. South Africa Neoantigens Market Outlook, by Product Type, 2020-2033
8.6.11. Egypt Neoantigens Market Outlook, by Type, 2020-2033
8.6.12. Egypt Neoantigens Market Outlook, by End User, 2020-2033
8.6.13. Egypt Neoantigens Market Outlook, by Application, 2020-2033
8.6.14. Egypt Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
8.6.15. Egypt Neoantigens Market Outlook, by Product Type, 2020-2033
8.6.16. Nigeria Neoantigens Market Outlook, by Type, 2020-2033
8.6.17. Nigeria Neoantigens Market Outlook, by End User, 2020-2033
8.6.18. Nigeria Neoantigens Market Outlook, by Application, 2020-2033
8.6.19. Nigeria Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
8.6.20. Nigeria Neoantigens Market Outlook, by Product Type, 2020-2033
8.6.21. Rest of Middle East Neoantigens Market Outlook, by Type, 2020-2033
8.6.22. Rest of Middle East Neoantigens Market Outlook, by End User, 2020-2033
8.6.23. Rest of Middle East Neoantigens Market Outlook, by Application, 2020-2033
8.6.24. Rest of Middle East Neoantigens Market Outlook, by Immunotherapy Type, 2020-2033
8.6.25. Rest of Middle East Neoantigens Market Outlook, by Product Type, 2020-2033
8.7. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. BioNTech SE
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Moderna, Inc.
9.4.3. Gritstone bio, Inc.
9.4.4. Neon Therapeutics / BioNTech
9.4.5. Genentech, Inc. / F. Hoffmann-La Roche Ltd.
9.4.6. Merck & Co., Inc.
9.4.7. Advaxis, Inc.
9.4.8. Nouscom AG
9.4.9. ISA Pharmaceuticals B.V.
9.4.10. Achilles Therapeutics plc
9.4.11. Personalis, Inc.
9.4.12. Agenus Inc.
9.4.13. Evaxion Biotech A/S
9.4.14. Vaccibody / Nykode Therapeutics ASA
9.4.15. Immatics N.V.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations